Vasomune Therapeutics Announces Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment

Vasomune, Inc., a clinical-stage biopharmaceutical company, announced the first subjects have been dosed in a Phase 1 study of AV-001 in healthy subjects. AV-001 is a first-in-class therapeutic that targets the Tie2 tyrosine kinase receptor, a key regulatory protein in the vasculature responsible for maintaining normal vascular function. Should the benefit demonstrated in animal studies translate to the clinic, AV-001 has the potential to improve survival and shorten the duration of hospitalization for patients hospitalized with COVID-19.